Mesothelioma statistics show that 2,000 to 3,000 people are diagnosed with mesothelioma each year in the United States. The asbestos-related disease accounts for less than 0.3 percent of all cancer diagnoses in the country.
Knowing key mesothelioma statistics and facts about asbestos can help you better understand this rare disease and make more educated decisions about your health.
Statistics from the American Cancer Society show approximately 3,000 new cases of mesothelioma in the U.S. each year. The majority of these cases stem from asbestos, which is the primary cause of the disease.
Annual U.S. asbestos use peaked at 803,000 metric tons in 1973, according to U.S. Geological Survey records. It declined to 1,700 metric tons by 2007.
Out of all people with heavy, prolonged exposure to asbestos, 2 to 10 percent develop pleural mesothelioma, the most common type of the asbestos-related cancer.
Who Gets Mesothelioma?
The typical mesothelioma patient is a man older than 65 with a blue-collar or military background. However, anyone with a history of asbestos exposure is at risk.
Need More Information About Mesothelioma?
Get our exclusive mesothelioma guide covering treatment information, legal help, clinical trial details, support and much more.
Occupations with Greatest Risk of Asbestos Exposure
Construction
Firefighting
Manufacturing
Chemical Refining
Power Generation
Shipbuilding
Military Service
Demographic Factors in Mesothelioma Incidence
Because men are exposed to asbestos more often, they are 4.6 times more likely to be diagnosed with mesothelioma. Of all diagnosed patients, 95 percent are white. Hispanics are diagnosed more frequently than blacks or Asians.
For people older than 60 years of age, the risk of developing the disease is 10 times higher than it is for people younger than 40.
Latency Period of Mesothelioma
The gap between the first exposure and the appearance of symptoms is called the latency period. Mesothelioma symptoms typically appear 20 to 50 years after exposure to asbestos.
Mesothelioma latency period timeline
Mesothelioma Facts
Mesothelioma is a complex disease, and very few doctors have experience diagnosing and treating it. Mesothelioma specialists offer patients the greatest hope.
Death Toll of Mesothelioma
From 1999 to 2015, a total of 45,221 Americans died from mesothelioma.
Nearly 80 percent of those deaths occurred among men.
About 37 percent of those who died were 75 to 84 years old.
Mesothelioma Deaths by State, 1999–2013
Nearly every highly populated state shows a heavy death toll.
Pleural Mesothelioma Survival Rates by Stage at Diagnosis
Doctors sort mesothelioma cases into stages to describe how far the cancer has spread. The mesothelioma stage at diagnosis affects the patient’s treatment options and prognosis.
Data from the American Cancer Society reveal the link between staging and survival rates.
Records show a low five-year survival rate for mesothelioma patients, no matter what their stage at diagnosis.
Source: American Cancer Society
Demographic Factors in Mesothelioma Survival Rates
Research shows women diagnosed with pleural mesothelioma experience nearly three-fold better survival than men. One 2014 study reported 13.4 percent of women survive for five years after treatment, compared to only 4.5 percent of men.
The one-year survival rate is about the same for all races. From three years on, survival is slightly worse for whites. National Cancer Institute data shows five-year survival among whites is 7.6 percent, compared to 12.3 percent for blacks.
Overall, younger patients have a significantly higher survival rate than older patients. More than 50 percent of patients diagnosed before the age of 50 survive one year, while less than 33 percent of those 75 or older survive the same length of time.
Most mesothelioma cases appear in the pleura (the tissue lining surrounding the lungs). A large fraction of cases appear in the peritoneum (the lining of the abdomen).
In very rare cases, the cancer forms in the pericardium (the lining of the heart) or the tunica vaginalis (the lining of the testicles).
Asbestos usually enters the body through the lungs, which is why mesothelioma most often develops in the pleura.
Mesothelioma Survival Rates by Site
Medical advances have made peritoneal mesothelioma easier to treat than pleural mesothelioma. A 2015 study from Translational Oncology reveals a large difference in survival rates.
The study data show that most patients survived a year after diagnosis, but longer-term survival rates were higher for peritoneal patients.
Source: Translational Oncology, 2015
Symptoms by Site
Mesothelioma symptoms vary depending on where the cancer forms. Mesothelioma can be challenging to diagnose because early-stage symptoms are usually mild or nonexistent.
Symptom
Pleural
Peritoneal
Pericardial
Abdominal Distention
Abdominal Swelling or Tenderness
Anemia
Loss of Appetite
Bowel Obstruction
Chest Pains
Chills
Cough
Couging up Blood
Difficulty Breathing
Fatigue
Feeling of Fullness
Fever
Fluid Buildup
Lumps Under Abdominal Skin
Lumps Under Skin of the Chest
Heart Failure
Heart Palpitations
Hernias
Irregular Heartbeat
Murmurs
Night Sweats
Pain
Pressure on the Heart
Reduced Chest Expansion
Shortness of Breath
Vomiting
Weight Loss
Wheezing
Benefits from Cancer Treatment
Mesothelioma treatment may involve surgery, chemotherapy and radiation therapy. Patients can also enroll in clinical trials to try experimental treatments such as immunotherapy.
Research has shown improved survival with multimodal therapy, an approach that combines two or more treatments. A 2007 study in the Journal of Thoracic Oncology reported a median survival time of 26 months when four therapies were combined.
Human studies called clinical trials give patients access to the latest breakthroughs in treatment. Researchers have conducted more than 300 clinical trials for mesothelioma worldwide.
The United States remains a powerhouse for medical research.
Source: ClinicalTrials.gov
Survival Rates with Traditional Therapy for Pleural Mesothelioma
A 2014 study in the Annals of Thoracic Surgery shows a clear survival advantage for surgery patients who also receive chemotherapy and radiation.
Chemotherapy and radiation can kill cancer cells left in the body after surgery.
Source: Annals of Thoracic Surgery, 2014
Combining surgery with chemotherapy is also effective for peritoneal mesothelioma. A 2015 study in the Annals of Surgical Oncology found 52 percent of patients live at least five years after surgery with hyperthermic intraperitoneal chemotherapy (HIPEC).
However, only about 20 percent of mesothelioma patients are eligible for aggressive tumor-removing surgery. For the rest, doctors are testing experimental drug regimens, including immunotherapy drugs already used in lung cancer treatment.
Immunotherapy Drugs Being Tested for Mesothelioma
Pembrolizumab (Keytruda)
Nivolumab (Opdivo)
Ipilimumab (Yervoy)
CRS-207
WT1 Vaccine
Mesothelioma Costs and Compensation
Costs: $60,000The National Cancer Institute estimates the cost of lung cancer treatment at more than $60,000 for the first year. Mesothelioma treatment costs are comparable.
Claims: $180,000The RAND Corporation estimated the median value for mesothelioma claims $180,000 in a 2010 research report.
Trusts: $30 BillionIn 2016, the RAND Corporation’s Institute for Civil Justice reported that asbestos bankruptcy trusts hold a combined total of more than $30 billion.
Karen Selby joined Asbestos.com in 2009. She is a registered nurse with a background in oncology and thoracic surgery and was the director of a tissue bank before becoming a Patient Advocate at The Mesothelioma Center. Karen has assisted surgeons with thoracic surgeries such as lung resections, lung transplants, pneumonectomies, pleurectomies and wedge resections. She is also a member of the Academy of Oncology Nurse & Patient Navigators. Read More
Taioli, E., Wolf, A., Camacho-Rivera, M., & Flores, R. (2014, June 11). Women with malignant pleural mesothelioma have a threefold better survival rate than men. Annals of Thoracic Surgery, 98(3), 1020-1024. doi: Retrieved from:
http://dx.doi.org/10.1016/j.athoracsur.2014.04.040
Neumann, V. et al. (2013). Malignant pleural mesothelioma. Deutsches Arzteblatt International, 110(18), 319-326. doi: 10.3238/arztebl.2013.0319
Porpodis, K. et al. (2013, September).Malignant pleural mesothelioma: Current and future perspectives. Journal of Thoracic Disease, 5(Suppl 4), S397–S406. doi: 10.3978/j.issn.2072-1439.2013.08.08
Centers for Disease Control and Prevention, National Center for Health Statistics. (2012). Underlying Cause of Death 1999-2010 on CDC WONDER Online Database. Retrieved from:
http://wonder.cdc.gov/ucd-icd10.html
Robinson, B.M. (2012). Malignant pleural mesothelioma: An epidemiological perspective. Annals of Cardiothoracic Surgery, 1(4), 491-496. doi: 10.3978/j.issn.2225-319X.2012.11.04
Weder, W., & Opitz, I. (2012, November). Multimodality therapy for malignant pleural mesothelioma. Annals of Cardiothoracic Surgery, 1(4), 502–507. doi: 10.3978/j.issn.2225-319X.2012.11.12
Delgermaa, V. et al. (2011, June 15). Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bulletin of the World Health Organization, 89, 716-724C. doi: 10.2471/BLT.11.086678
Park, E. et al. (2011). Global Magnitude of reported and unreported mesothelioma. Environmental Health Perspectives, 119, 514-518. Retrieved from:
http://dx.doi.org/10.1289/ehp.1002845
Lucchi, M. et al. (2007). Four-modality therapy in malignant pleural mesothelioma: A phase II study. J Thorac Oncol., 2(3), 237-42. doi: 10.1097/JTO.0b013e318031d05c
Pass, H., Vogelzang, N., & Carbone, M. Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis and Translational Therapies. Springer: New York, 2005.
Odgerel, C. et al. (2017). Estimation of the global burden of mesothelioma deaths from incomplete national mortality data. Occup Environ Med., 74, 851-858. Retrieved from:
http://dx.doi.org/10.1136/oemed-2017-104298
Spaggiari, L. et al. (2014, June). Extrapleural pneumonectomy for malignant mesothelioma: an Italian multicenter retrospective study. Retrieved from:
https://www.ncbi.nlm.nih.gov/pubmed/24726598
Pleural
Peritoneal
Pericardial
